Aptevo Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
APVO$1.08-4.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEM ENTS OF CASH FLOWS
(in thousands)
| For the Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating Activities | ||
| Net (loss) income | $(17,411) | $8,027 |
| Adjustments to reconcile (loss) income to net cash used in operating activities: | ||
| Stock-based compensation | 2,193 | 1,802 |
| Depreciation and amortization | 567 | 901 |
| Loss on disposal of property and equipment | — | 47 |
| Non-cash interest expense and other | 10 | 3,239 |
| Gain on extinguishment of liability related to sale of royalties | — | (37,182) |
| Changes in operating assets and liabilities: | ||
| Royalty receivable | 2,500 | 1,164 |
| Prepaid expenses and other current assets | 153 | 355 |
| Operating lease right-of-use asset | 422 | 653 |
| Accounts payable, accrued compensation and other liabilities | 518 | (394) |
| Long-term operating lease liability | (682) | 366 |
| Net cash used in operating activities | (11,730) | (21,022) |
| Investing Activities | ||
| Purchases of property and equipment | — | (29) |
| Net cash used in investing activities | — | (29) |
| Financing Activities | ||
| Payments of long-term debt, including fees | (3,467) | (12,267) |
| Repayments under liability related to sale of royalties | — | (6,779) |
| Value of equity awards withheld for tax liability | (10) | (4) |
| Proceeds from exercises of warrants | 3,047 | — |
| Proceeds from milestones related to sale of royalties | — | 10,000 |
| Transaction costs for milestones related to sale of royalties | — | (500) |
| Proceeds from issuance of common stock and prefunded warrants | 6,428 | 6,934 |
| Net cash provided by (used in) financing activities | 5,998 | (2,616) |
| (Decrease) in cash and cash equivalents | (5,732) | (23,667) |
| Cash and cash equivalents at beginning of period | 22,636 | 46,303 |
| Cash and cash equivalents at end of period | $16,904 | $22,636 |
| Supplemental Cash Flow Information | ||
| Warrant modification - incremental value | $2,080 | $— |
| Change in right-of-use asset and lease liability from lease remeasurement | $— | $4,372 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.